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Introduction
Axillary lymph node (ALN) status is an important prognostic factor and a major determinant for postoperative treatment decision-making for breast cancer patients 1, 2 . ALN staging evolved together with the shift in surgical treatment from the largest tolerable surgery to less invasive surgery. During this process, sentinel lymph node biopsy (SLNB) replaced ALN dissection and has become the standard of care for ALN staging in breast cancer patients with clinically negative ALN for over 10 years. SLNB has significantly reduced the incidence of surgical complications such as upper limb lymphedema and impaired shoulder function, and has improved patients' quality of life without compromising their survival [3] [4] [5] [6] [7] . However, the surgical complications from SLNB cannot be ignored.
Lymphedema occurs in approximately 5-8% of patients receiving a SLNB and paresthesia in 10-15% [6] [7] [8] [9] [10] [11] [12] . In addition, 28-49% of the patients experience shoulder-arm function impairment [11] [12] [13] . Notably, 60-70% of the patients receiving a SLNB are shown to have negative SLNs after histopathological analysis and thus do not benefit from the procedure 4, 14, 15 .
Due to early detection through the national screening program, more patients are being diagnosed with early breast cancer and are more often free from ALN metastasis 16 . If patients with a pathologically negative ALN can be preoperatively predicted, omission of axillary surgery could avoid the above-mentioned surgical complications and improve their quality of life, without affecting the postoperative treatment decision-making. Consequently, accurate assessment of the preoperative patients' risk of ALN metastasis is required. However, all currently used imaging modalities have low sensitivity in predicting ALN metastasis, resulting in a false-negative prediction of around 40-70% [17] [18] [19] [20] .
Therefore, new tools for prediction of preoperative ALN metastasis are urgently needed.
We previously developed a predictive model for ALN metastasis in a Chinese breast cancer population based on clinicopathological features from the primary tumor and axillary ultrasound 21 . The model was In this study we validated the performance of the Chinese model for predicting ALN metastasis in a large Dutch breast cancer population. The model was updated using the Dutch and Chinese patient M A N U S C R I P T
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4 data in order to improve its discriminative performance and predictive accuracy and maintain its generalizability in different ethnic groups.
Methods

Patients
We selected all women with primary breast cancer who underwent breast surgery and axillary staging at six participating Dutch hospitals (one university hospital, two teaching and referral hospitals and three general hospitals) between 2011 and 2015 from the Netherlands Cancer Registry (NCR). The NCR records data on all cancer patients in the Netherlands. The inclusion and exclusion criteria were the same with that used in the initial study which developed the model 21 . . This study was approved by all participating hospitals.
Data collection
From the NCR we collected data on age at diagnosis, menopausal status, tumor location, histological .
Statistical analysis
Differences of categorical and continuous variables between groups were analyzed using the Chisquare and Mann-Whitney U test, respectively. The clinical value for each predictor in the original model was used to calculate the ALN metastasis probability for each patient in the present study. The AUC was used to evaluate the discriminative performance of the model. For the calibration of the original model, the enrolled Dutch patients were sorted on their predicted probability and grouped into three equally sized groups. For each group, the mean model-predicted probability and the actual To improve its discriminative performance and predictive accuracy, we updated the original model using both the Dutch and the Chinese populations as follows. Generalized linear model (GLM) tree analysis was applied to the Dutch and Chinese patient populations to classify patients into groups with different risk of ALN metastasis based on their clinicopathological characteristics. In each group, the model was updated separately by adjusting the intercept and slope of the original model. Detailed information on GLM tree analysis is provided in the Supplementary Methods. The AUC and calibration plot were used to assess the discriminative performance and predictive accuracy of the updated models. False-negative rates (FNRs) of the updated models at several cut-off points for the predicted probability were calculated to assess their clinical usefulness. FNR was considered acceptable if it was lower than 10%. All statistical tests were two-sided, and a P-value <0.05 was considered to be statistically significant. Statistical analyses were performed using the statistical software SPSS, version 19 and R, version 3.3.2.
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Results
Patient characteristics
In total, 1,416 out of 2,227 Dutch breast cancer patients were included ( Fig.1 Table S1 .
Discrimination performance and predictive accuracy of the original Chinese model
The AUC of the original model was 0.774 (95% CI 0.743-0.804) when it was applied to the entire Dutch population (Fig. 2a) , whereas the AUCs for each hospital ranged from 0.705 to 0.848 (Fig. S1 ).
The mean model-predicted probability and the actual percentage of patients with ALN metastasis for each group are shown in Table S2 . In all groups, except for group 1 (ALN metastasis low-risk group) including patients with a mean model-predicted probability lower than 10.0%, the mean modelpredicted probabilities were within the 95% CI of the actual percentage of patients with ALN metastasis. In Fig. 2b , the calibration plot showed less optimal agreement between the model prediction and the actual observation, especially for group 1. 
Update of the original model
had the highest rate (70.2%) of ALN metastasis (Fig. 3) . The updated models for each group are shown in Table S3 .
Discrimination performance and predictive accuracy of the updated models
Based on the GLM tree analysis, the Dutch validation patients were first classified into different groups according to their ALN cortical thickness and clinical tumor size of the primary tumor. Subsequently, their predicted probabilities of ALN metastasis were calculated using the corresponding updated model for each group (Table S3 ). The AUC of the updated models for the entire Dutch patient population was 0.812 (95% CI 0.784-0.840) (Fig. 2c) . The AUCs of the updated models for each hospital ranged from 0.730 to 0.874, which were all higher than the corresponding AUCs of the original model ( Fig. S1 and   S2 ). The mean model-predicted probability and the actual percentage of patients with ALN metastasis for each group are shown in Table S4 . In all groups, the model-predicted probabilities were within the 95% CI of the actual percentage of patients with ALN metastasis, showing better predictive accuracy compared with the original model, especially for group 1 (Table S2 and S4). The calibration plot for the updated models showed almost perfect agreement between the model prediction and the actual observation (Fig. 2d) .
Clinical usefulness of the updated models
FNRs of the updated models at several model-predicted probability cut-off points are shown in Table 2 .
By using cut-off points, we considered patients with a model-predicted probability less than or equal to the cut-off point to have negative ALNs. Since the generally accepted FNR for SLNB was 10.0%, we considered this percentage acceptable in our study. Using this criterion, the FNR of the updated models (7.9%) was acceptable when the model-predicted probability cut-off point was set at 12.0%.
Using the updated models, 415 patients (29.3% of entire study population) could have been selected for axillary surgery omission. When combined with FNAC for those patients with lymph node cortical thickness larger than 2.3mm, the FNR of our model could have been reduced to 6.2%.
Discussion
In this study we validated and updated a previously developed model 21 , providing a reliable tool for preoperative assessment of the risk of ALN metastasis. This tool could assist clinicians in determining the optimal treatment strategy of axillary staging for individual patients.
In this study, the Dutch patients presented more favorable prognostic clinicopathological features M A N U S C R I P T
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8 compared with the Chinese patients. This disparity could partly be due to the different ethnic backgrounds of the two study populations 25 . In addition, the routinely performed nationwide screening programme in the Netherlands (which is absent in China) may be another contribution to this difference, since this leads to an increasing number of early diagnoses 26 . Despite the differences in clinicopathological features between the two study populations, the original model already showed a good discriminative performance with an AUC of 0.774. This indicates a good generalizability of the model to patients of different ethnic origins. However, the original model underestimated the ALN metastasis probability in the low-risk Dutch patient group with an ALN metastatic rate of 10.0%; a similar underestimation was found in the Chinese study 21 . Moreover, these results may indicate that different models for different ALN metastasis risk groups are required to improve the prediction. In order to refine the predictive accuracy of the model in several risk-based subgroups and maintain generalizability to different ethnic groups, we performed GLM tree analysis using data of both the Dutch and Chinese patients. After creating different risk groups, the discriminative performance and predictive accuracy of the updated models improved in the Dutch patients, especially for low-risk patients with a mean model-predicted probability lower than 10.0%. In a sensitivity analysis, the SLNB remains the standard of care for axillary staging in patients with clinically negative nodes. In order to avoid its complications, omission of axillary surgery in ALN metastasis low-risk patients has gained more interest. Several ongoing clinical trials are investigating this topic 27 . Most of these trials enrol patients based on a preoperative ultrasound with or without FNAC. However, the FNR of ALN metastasis prediction by a preoperative ultrasound has been reported to be as high as around 30-55% [17] [18] [19] 28 . Other imaging modalities e.g. magnetic resonance imaging (MRI) or positron emission tomography-computed tomography (PET-CT) have also been reported to predict the risk of ALN metastasis with a high FNR (MRI 18% vs PET-CT 36%) 29 . Moreover, these imaging modalities are too expensive to be applied for every patient. To the best of our knowledge, this is the first model that predicts the risk of ALN metastasis in patients with ALNs detected by a preoperative ultrasound. For most of these patients, it is very difficult to judge whether the detected lymph nodes are malignant or not, merely based on their ultrasound morphology.
Clinically, a FNAC is performed when suspicious lymph nodes are found. The FNR of ALN metastasis prediction by FNAC is higher than 20%
32
. In contrast, our updated models had a lower FNR (7.9%) in predicting the ALN status when the cut-off point was set at 12.0%. More importantly, this FNR is even lower when combined with a FNAC. These results suggest that axillary surgery omission could be possible for patients with a predicted probability lower than 12.0% by using the updated models, especially when combined with FNAC; this group accounts for 29.3% of the entire patient cohort in this 
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
This study has several strengths. First, it is a multicenter validation study. The six participating hospitals are from different areas of the Netherlands. Therefore, the enrolled patients in our study are representative for the whole breast cancer population in the Netherlands. Our updated models show a very good discriminative performance in all participating hospitals, indicating good generalizability of the models. Second, the necessary data for all of the six variables incorporated in our models can be obtained preoperatively, for example, by a core needle biopsy of the primary tumor and axillary ultrasound examination. This would facilitate the application of our models. Third, our updated models are easy to use. After all the necessary data for the six variables are obtained, patients can be grouped into one of the different risk groups based on their cortical thickness of the lymph node detected by ultrasound and the clinical tumor size, as shown in Fig.3 . Subsequently, the probability of ALN metastasis for an individual patient can be calculated using the corresponding formula demonstrated in Table S3 . A user-friendly web-based calculator based on our updated models has been developed and will be published online to facilitate the use of our models (https://www.evidencio.com/models/show/999).
There are limitations of this study. First, the ER status and grade of the primary tumor were obtained from surgical specimens and not from core needle biopsies in our study. Since breast cancer is highly heterogeneous, discrepancies between the ER status and tumor grade of core needle biopsies and the whole surgical specimen may arise. Several studies have demonstrated that the discrepancy of ER positive rates analysis on core needle biopsies and subsequent excision specimen from the same patient was only 2-3% 34, 35 . We therefore do not expect that this influences the model validity. However, discrepancy of tumor grade between core needle biopsies and excision specimen was reported to be near 30% in a recent meta-analysis 36 . It may be that this discrepancy has influence on the performance of the model. However, it is not clear whether this will also influence the FNR of the models in predicting ALN metastasis low-risk patients. Second, the FNR (7.9%), which we considered might be suitable for selecting patients to avoid axillary surgery, was calculated on the basis of FNR of SLNB from 75.0% of patients received SLNB only. This means that the real FNR of our model is higher than 7.9% and theoretically lower than 17.9%. Given the improvement of systemic treatments for breast cancer, the impact of residual metastatic disease in ALNs on survival of patients has become less important. This has been proved by results from IBCSG 23-01 and Z0011 trials, which demonstrated 13.0% and 27.3% of patients had metastatic non-SLN being left behind in the non-M A N U S C R I P T
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ALND group without affecting patients' long term recurrence and survival 33, 37 . Third, the axillary ultrasound is an operator-dependent technique. Measurement of the three ultrasound variables incorporated in our models may differ when performed by different doctors due to inter-observer variability. However, an experienced radiologist can almost always identify ALNs and access their morphology if they are present 28, 38, 39 . Therefore, we recommend an experienced radiologist to assess the ALN when using our models. Finally, this is a study based on retrospectively collected data from a cancer registry. Harmonization of data measurement was less optimal. Nevertheless, data was uniformly collected by trained data managers according to strict coding manuals. Together, a validation of our models using core needle biopsies in each center is recommended before using the models in clinical practice to assist decision-making on surgical treatment of the axilla.
Conclusions
We successfully validated and updated our previously published model in a multicenter Dutch breast hilum of lymph nodes, c=0 when presence and c=1 when absence, d1 and d2: d1=1 and d2=0 when histological tumor grade 2, d1=0 and d2=1 when histological tumor grade 3, e: clinical tumor size, continuous variable, f: tumor estrogen receptor status, f=0 when ER is negative, f=1 when ER+, f=2 when ER2+ and f=3 when ER3+, p in the formulas: the predictive probability of axillary lymph node metastasis.
